IN8bio, Inc. (INAB) Stock Forecast
INAB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +530.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.57
- 52-week range
- $0.96 – $2.59
INAB analyst ratings
3 analystsNumber of analysts at each rating.
INAB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
INAB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.57 | −$0.22 | −$0.85 | +60.4% | 3 |
| Current fiscal year (2026) | −$1.11 | −$1.49 | −$0.89 | −$4.44 | +74.9% | 3 |
| Next fiscal year (2027) | −$0.95 | −$1.24 | −$0.64 | −$1.11 | +14.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
INAB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $1.1M | $0 | $3.3M | 0.0% | 3 |
INAB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
INAB revenue: reported and forecast
INAB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.38 | −$0.38 | −$0.38 | −$0.34 | +49.6% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.24 | −$1.24 | −$1.09 | −$1.09 | −$1.11 | −10.4% | 2 up · 2 down |
| Next fiscal year (2027) | −$1.06 | −$1.06 | −$0.96 | −$0.96 | −$0.95 | −10.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
INAB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; INAB beat in 7 of 12.
What analysts expect from INAB
3 analysts cover IN8bio; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 530.6% above the latest close of $1.11. Analysts expect earnings of −$1.11 per share for 2026, +74.9% from a year earlier. For 2027 the average estimate is −$0.95 per share on revenue of $1.1 million. IN8bio beat the EPS estimate in 7 of the last 12 quarters.
Related: INAB income statement, INAB key metrics, INAB chart. See the INAB stock overview for the latest quote and news.
INAB forecast FAQ
What is IN8bio's price target?
The average analyst price target for IN8bio is $7.00, 530.6% above the latest close of $1.11.
Is IN8bio a buy, hold or sell?
Of 3 analysts covering IN8bio, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is IN8bio's EPS forecast?
Analysts forecast −$1.11 per share for 2026 (range −$1.49 to −$0.89); for 2027 the estimate is −$0.95.
When does IN8bio report earnings?
IN8bio is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.57.
Does IN8bio usually beat earnings estimates?
IN8bio reported EPS at or above the analyst estimate in 7 of the last 12 quarters.